New dialysis solution may delay need for full treatment in kidney patients

NCT ID NCT05721404

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether using icodextrin, a special dialysis solution, can help people on peritoneal dialysis (a type of home dialysis for kidney failure) stay on a lower-dose regimen for longer. Participants are randomly assigned to receive either icodextrin or a standard sugar-based solution when they show signs of fluid overload. The goal is to see if icodextrin delays the need to switch to full-dose dialysis and improves outcomes like infection rates and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Icodextrin peritoneal dialysis solution
What this could lead to
If it works, this could help people on peritoneal dialysis maintain a lower treatment burden for longer, with less glucose exposure and potentially fewer complications.
What could go wrong
This is a single-center Phase 4 trial with 194 participants, so results may not apply broadly. The benefit may be modest, and icodextrin can cause side effects like skin reactions or sterile peritonitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.